R&G PharmaStudies Co. Ltd. A (301333) — Cash Flow Reinvestment Rate
R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow Reinvestment Rate of 0.33x as of June 2022, reinvesting CN¥13.67 Million (capex CN¥5.24 Million plus investments CN¥8.43 Million) from operating cash flow of CN¥40.98 Million. See 301333 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
R&G PharmaStudies Co. Ltd. A Cash Flow Reinvestment Rate (2019–2025)
Historical reinvestment intensity for R&G PharmaStudies Co. Ltd. A across 7 annual periods. For the full cash flow conversion analysis, see R&G PharmaStudies Co. Ltd. A cash flow conversion.
Annual Cash Flow Reinvestment Rate for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year capital reinvestment analysis for R&G PharmaStudies Co. Ltd. A. See financial flexibility index of R&G PharmaStudies Co. Ltd. A to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.71x | CN¥81.65 Million | CN¥114.20 Million | CN¥19.28 Million | ▲ +380.4% |
| 2024 | 0.15x | CN¥23.03 Million | CN¥154.76 Million | CN¥19.98 Million | ▼ -96.0% |
| 2023 | 3.76x | CN¥724.68 Million | CN¥192.56 Million | CN¥19.88 Million | ▲ +1417.0% |
| 2022 | 0.25x | CN¥32.37 Million | CN¥130.47 Million | CN¥20.83 Million | ▼ -61.5% |
| 2021 | 0.64x | CN¥73.87 Million | CN¥114.57 Million | CN¥38.28 Million | ▼ -39.9% |
| 2020 | 1.07x | CN¥47.33 Million | CN¥44.10 Million | CN¥25.48 Million | ▲ +126.5% |
| 2019 | 0.47x | CN¥49.03 Million | CN¥103.48 Million | CN¥26.00 Million | — |